Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2009
11/05/2009WO2009033797A3 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection
11/05/2009WO2009033785A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
11/05/2009WO2009033784A3 Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
11/05/2009WO2009033738A3 Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
11/05/2009WO2009033712A3 Use of melanotan ii as a therapeutic agent
11/05/2009WO2009027086A3 Use of vitex agnus castus extracts for preparing a medicament
11/05/2009WO2008157408A8 Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
11/05/2009WO2008097503A8 Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
11/05/2009US20090276090 Dose dispensing system and apparatus
11/05/2009US20090275751 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
11/05/2009US20090275670 Dog pheromone formulation and delivery system
11/05/2009US20090275653 Polymorphic forms of ladostigil tartrate
11/05/2009US20090275629 Therapy for the treatment of disease
11/05/2009US20090275626 Pharmaceutical composition for prevention or treatment of neurogenic pain
11/05/2009US20090275624 Inhibitors of cdc phosphatases
11/05/2009US20090275618 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as cb1 receptor modulators
11/05/2009US20090275617 such as 3-[(1S,3R)-3-fluorocyclopentylamino]methyl-5-(5-fluoro-6-methylpyridin-3-yl)-1-isopropyl-4-methyl-1H-pyrazole, having opioid receptor antagonistic activity, used analgesics or for the treatment of diabetes, neurodegenerative diseases, drug abuse, hypotension, schizophrenia , dementia or obesity
11/05/2009US20090275616 Straightforward entry to 7-azabicyclo[2.2.1]heptane-1-carbonitriles and subsequent synthesis of epibatidine analogues
11/05/2009US20090275614 Methylphenidate Derivatives and Uses of Them
11/05/2009US20090275611 Compounds Which Modulate The CB2 Receptor
11/05/2009US20090275610 Tricyclic opioid modulators
11/05/2009US20090275602 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
11/05/2009US20090275600 Modified pyrimidine glucocorticoid receptor modulators
11/05/2009US20090275596 Treatment of Neurodegenerative Disorders with Thiourea Compounds
11/05/2009US20090275587 Methods of treating ischemic related conditions
11/05/2009US20090275580 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof
11/05/2009US20090275579 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof
11/05/2009US20090275576 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
11/05/2009US20090275574 Novel compounds-300
11/05/2009US20090275568 Fused quinoline derivative and use thereof
11/05/2009US20090275566 Bace inhibitors
11/05/2009US20090275563 Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy
11/05/2009US20090275550 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension
11/05/2009US20090275548 Compounds and methods for activated therapy
11/05/2009US20090275539 Nuclear Transcription Factors Regulators
11/05/2009US20090275538 Arylmethylidene heterocycles as novel analgesics
11/05/2009US20090275537 Certain chemical entities, compositions, and methods
11/05/2009US20090275501 Somatostatin-dopamine chimeric analogs
11/05/2009US20090275498 Novel peptides
11/05/2009US20090274775 reducing the risk of suicide associated with the use of a psychoactive drug by administering a lithium salt as cotherapy with said psychoactive drug
11/05/2009US20090274765 Compositions and Methods for Drug Delivery
11/05/2009US20090274720 Anti-dementia substance from hericium erinaceum and method of extraction
11/05/2009US20090274707 Anti-IL-12 Antibodies, Nucleic Acids Encoding Antibodies, and Methods of Production
11/05/2009US20090274691 Use of CD25 binding molecules in steroid-resistant patients
11/05/2009US20090274690 Stimulating remyelination of central nervous system axons by administering a monoclonal antibody characterized by their ability to bind structures and cells within the central nervous system, including oligodendrocytes; including neural dysfunction caused by spinal cord injury
11/05/2009US20090274680 Human Phospholipases
11/05/2009US20090274675 Migraine tonic
11/05/2009US20090274668 Combined Regulation of Neural Cell Production
11/05/2009DE102008020127A1 Kompartimentspezifische Pflanzenextraktkombination aus Ginkgo biloba- und Ginseng-Extrakt mit Tandemwirkung Compartment specific combination of ginkgo biloba plant extract and ginseng extract with tandem effect
11/05/2009CA2729053A1 Vinyl substituted fatty acids
11/05/2009CA2725128A1 Neurotrophic factor manf and uses thereof
11/05/2009CA2723207A1 Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
11/05/2009CA2723062A1 Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethylphenyl) methylcarboxamides as nk1 tachikynin receptor antagonists
11/05/2009CA2722986A1 Modulators of dopamine neurotransmission
11/05/2009CA2722978A1 Modulators of dopamine neurotransmission
11/05/2009CA2722938A1 New peptidomimetic compounds
11/05/2009CA2722923A1 Indazole compounds as ccr1 receptor antagonists
11/05/2009CA2722798A1 Synthesis of timosaponin bii
11/05/2009CA2722743A1 Novel formulations for treatment of migraine
11/05/2009CA2722577A1 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
11/05/2009CA2722453A1 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
11/05/2009CA2722347A1 Piperidine and pyrrolidine compounds
11/05/2009CA2722314A1 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
11/05/2009CA2722295A1 Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
11/05/2009CA2722121A1 A homeopathic formulation
11/04/2009EP2113509A2 Modulation of the expression of STAT-1 dependent genes
11/04/2009EP2113504A1 Preparation of N-6 demethylated, 9,10-dihydrolysergic acid alkyl esters
11/04/2009EP2113315A2 Disposal system for transdermal dosage form
11/04/2009EP2113285A1 Role of (de)acetylation in counteracting protein aggregation
11/04/2009EP2112993A1 Substituted tetrahydropyrrolopyrazine compounds having affinity with the kcnq2/3 k+ channel and use thereof in medicaments
11/04/2009EP1931341B1 1h-indole-pyridinecarboxamide and 1h-indole-piperidinecarboxamide derivatives and their use as tyrosine hydroxylase inducers
11/04/2009EP1817296B1 Potentiators of glutamate receptors
11/04/2009EP1553092B1 Aralkyl formyl-alkyl piperazine derivatives and their uses as cerebral nerve protective agent
11/04/2009EP1446387B1 Substituted aryl 1,4-pyrazine derivatives
11/04/2009EP1432700B1 Spiro-hydantoin compounds useful as anti-inflammatory agents
11/04/2009EP1425011B1 Enhancement of learning and memory and treatment of amnesia
11/04/2009EP1372638B1 Cannabinoids for the treatment of breathing disorders during sleep
11/04/2009EP1311488B1 Substituted imidazoles as tafia inhibitors
11/04/2009EP1140039B1 Transparent transdermal nicotine delivery devices
11/04/2009CN101573354A Substituted isoquinolines and their use as Rho-kinase inhibitors
11/04/2009CN101570528A Glycyrrhizin derivatives and preparation and use thereof
11/03/2009US7612238 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases
11/03/2009US7612225 Endothelin receptor antagonist, useful for treating various circulatory system diseases such as hypertension, ischemic disorders, cerebral circulatory disorders, renal disorders, circulatory insufficiency of various organs, asthma, stroke
11/03/2009US7612183 Antibodies to myelin associated glycoprotein (MAG); neurological diseases/disorders
11/03/2009US7612114 Selective estrogen receptor modulator
11/03/2009US7612113 Hydroxy tetrahydro-naphthalenylurea derivatives
11/03/2009US7612090 Use in treatment of a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine
11/03/2009US7612086 Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation
11/03/2009US7612083 Urea substituted imidazoquinoline ethers
11/03/2009US7612079 2-(hydroxypiperidin-1-yl or hydroxyisoalkylamino)-6(3-nitrophenylamino, 3,4-dimethoxybenzylamino, pyrid-2-yl-methylamino, pyrid-4-yl-methylamino or indan-5-amino)-9-(isopropyl or cyclopentyl)purines; cell cyclin kinase inhibitors for treating cancer, leukemia, psoriasis and neuronal apoptosis
11/03/2009US7612078 Piperidinylamino-thieno[2,3-D] pyrimidine compounds
11/03/2009US7612075 Anticaogulants; cardiovascular disorders
11/03/2009US7612068 (S)-1-{2-[2-(4-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid; glycine transport inhibitors; for schizophrenia and other psychoses
11/03/2009US7612067 Imidazopyridazine compounds
11/03/2009US7612066 1-(3-tert-butyl-4-methoxy-5-morpholinophenyl)-2-(5,6-diethoxy-7-fluoro-1-imino-1,3-dihydroisoindol-2-yl)ethanone,; stabilizing the composition; not decompose even when placed under humidification conditions
11/03/2009US7612061 trans-1-{2-[(3,5-dibromobenzyl)oxy]-1,2,3,4-tetrahydronaphth-1-yl}-1,4-diazepane; serotonin reuptake inhibitor and/or neurokinin NK1 antagonist; antidepressant, anxiolytic agent; cognition activator; psychological disorders; obesity, gastrointestinal disorders
11/03/2009US7611865 Genetic engineering
11/03/2009US7611848 Measuring the activity of recombinant GPCR-III-Delta ) depleted of the extracellular domain of the corresponding native GPCR-III, in the presence of a given compound, compared to that of the GPCR-III- Delta in the absence of the compound; psychlogical and nervous disorders; food additives
11/03/2009US7611734 Use of extracts from Pelargonium species
11/03/2009US7611730 Containing racemate of tramadol in slow-release form and (+)enantiomer of tramadol in immediate-release form; analgesic efficacy results from interplay of enantiomers by mechanism which includes non-opioid and opiod components
1 ... 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 ... 1833